Combination of PD-1/PD-L1 and CTLA-4 inhibitors in the treatment of cancer - a brief update.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search or meta-analytic data
PubMed 41159031 · doi:10.3389/fimmu.2025.1680838
What was done
This narrative review summarized the current clinical landscape of dual immune checkpoint blockade targeting PD-1/PD-L1 alongside CTLA-4, focusing on FDA-approved regimens (nivolumab plus ipilimumab, durvalumab plus tremelimumab), their therapeutic indications, efficacy profiles, and safety considerations.
What was found
The abstract reports no quantitative figures or statistical values. It states that dual blockade demonstrates improved response rates, overall survival, and progression-free survival in melanoma, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, pleural mesothelioma, and esophageal squamous cell carcinoma. In contrast, limited efficacy was noted in glioblastoma, head and neck squamous cell carcinoma, and Merkel cell carcinoma. Additionally, the combination is noted to cause higher rates of multisystem immune-related adverse events relative to monotherapy.
Why it matters
The review contextualizes the trade-offs between enhanced anti-tumor synergy and elevated toxicity across approved and investigational indications for dual checkpoint inhibitor regimens.
Limits
This is a narrative review with no primary patient data, systematic search criteria, quality appraisal of included studies, or pooled meta-analytic effect sizes provided in the abstract. Exact event rates, response percentages, and toxicity figures are omitted.
Cited by
- supports There are over 100 different types of chemotherapy drugs and dozens of approved immunotherapies for cancer.